Research programme: brain injury therapies - Edge Therapeutics

Drug Profile

Research programme: brain injury therapies - Edge Therapeutics

Alternative Names: EG-1960; EG-1961; EG-1964; NimoGel™

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edge Therapeutics
  • Developer Edge Therapeutics; University of Toronto
  • Class Dihydropyridines; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists; Chymotrypsin inhibitors; Kallikrein inhibitors; Plasmin inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Neurological disorders
  • No development reported Brain injuries; Cerebral ischaemia; Subdural haematoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia(Prevention) in USA (Intracerebral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Subdural-haematoma(Prevention) in USA (Intracerebral)
  • 04 Nov 2017 No recent reports of development identified for research development in Brain injuries(Prevention) in North America (Intracerebral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top